Three things to know:
1. Varian Medical will acquire Oncozene, Embozene and Embozene Tandem, Boston Scientific’s products that treat arteriovenous malformations in the brain and spine.
2. The three products accumulated $21.2 million in sales in 2018.
3. The deal will be completed after Boston Scientific finalizes the acquisition of BTG, expected in August.
More articles on devices:
8 leadership changes in spine, orthopedic device companies in June
Fusion Robotics to advance spinal robotic devices
Alexion drug receives FDA approval for rare autoimmune disease of spinal cord
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.